Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Pan Tong

dblp:121/5279 · DBLP profile ↗
← Back
4ranked-venue papers
3as first author
0since 2021 · last 2019
0000-0002-1929-6492ORCID · corroborated

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 4 · 3 first-author

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
4 papers
Bioinformatics and computational biology · 88% Medical and health informatics · 12%

Topics — the 7 heaviest of 8, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery
drug combination analysis
0.412019
Response envelope analysis for quantitative evaluation of drug combinations · Bioinform. 2019
Bioinformatics and computational biology › drug discovery › drug combination analysis
synergy quantification
0.412019
Response envelope analysis for quantitative evaluation of drug combinations · Bioinform. 2019
Medical and health informatics
dose-response modeling
0.212015
drexplorer: A tool to explore dose-response relationships and drug-drug interactions · Bioinform. 2015
Bioinformatics and computational biology › clinical bioinformatics
drug response analysis
0.212015
drexplorer: A tool to explore dose-response relationships and drug-drug interactions · Bioinform. 2015
Bioinformatics and computational biology
gene expression analysis
0.212013
SIBER: systematic identification of bimodally expressed genes using RNAseq data · Bioinform. 2013
Bioinformatics and computational biology › transcriptomics
RNA-seq analysis
0.212013
SIBER: systematic identification of bimodally expressed genes using RNAseq data · Bioinform. 2013
Bioinformatics and computational biology
cancer genomics
0.112012
integIRTy: a method to identify genes altered in cancer by accounting for multiple mechanisms of regulation using item response theory · Bioinform. 2012

Methods — techniques the papers use, named apart from their topics

loewe additivity · 0.4bliss independence · 0.43d response surfaces · 0.4nonlinear dose-response modeling · 0.2IC50 estimation · 0.2lognormal mixture model · 0.2kurtosis analysis · 0.2clustering · 0.2item response theory · 0.1
YearPublicationVenuePosition
2019 Response envelope analysis for quantitative evaluation of drug combinations
abstract
MOTIVATION: The concept of synergy between two agents, over a century old, is important to the fields of biology, chemistry, pharmacology and medicine. A key step in drug combination analysis is the selection of an additivity model to identify combination effects including synergy, additivity and antagonism. Existing methods for identifying and interpreting those combination effects have limitations. RESULTS: We present here a computational framework, termed response envelope analysis (REA), that makes use of 3D response surfaces formed by generalized Loewe Additivity and Bliss Independence models of interaction to evaluate drug combination effects. Because the two models imply two extreme limits of drug interaction (mutually exclusive and mutually non-exclusive), a response envelope defined by them provides a quantitatively stringent additivity model for identifying combination effects without knowing the inhibition mechanism. As a demonstration, we apply REA to representative published data from large screens of anticancer and antibiotic combinations. We show that REA is more accurate than existing methods and provides more consistent results in the context of cross-experiment evaluation. AVAILABILITY AND IMPLEMENTATION: The open-source software package associated with REA is available at: https://github.com/4dsoftware/rea. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Di Du, Chia-Hua Chang, Pan Tong, Wai Kin Chan, Yulun Chiu, Bo Peng 0001, Lin Tan 0002, John N. Weinstein, Philip L. Lorenzi
Bioinform.4
2015 drexplorer: A tool to explore dose-response relationships and drug-drug interactions
abstract
Abstract Motivation: Nonlinear dose–response models are primary tools for estimating the potency [e.g. half-maximum inhibitory concentration (IC) known as IC50] of anti-cancer drugs. We present drexplorer software, which enables biologists to evaluate replicate reproducibility, detect outlier data points, fit different models, select the best model, estimate IC values at different percentiles and assess drug–drug interactions. drexplorer serves as a computation engine within the R environment and a graphical interface for users who do not have programming backgrounds. Availability and implementation: The drexplorer R package is freely available from GitHub at https://github.com/nickytong/drexplorer. A graphical user interface is shipped with the package. Contact: [email protected] Supplementary information: Supplementary data are available at Bioinformatics online.
Pan Tong, Kevin R. Coombes, Faye M. Johnson, Lauren A. Byers, Lixia Diao, Diane D. Liu, J. Jack Lee, John V. Heymach, Jing Wang 0006
Bioinform.1
2013 SIBER: systematic identification of bimodally expressed genes using RNAseq data
abstract
MOTIVATION: Identification of bimodally expressed genes is an important task, as genes with bimodal expression play important roles in cell differentiation, signalling and disease progression. Several useful algorithms have been developed to identify bimodal genes from microarray data. Currently, no method can deal with data from next-generation sequencing, which is emerging as a replacement technology for microarrays. RESULTS: We present SIBER (systematic identification of bimodally expressed genes using RNAseq data) for effectively identifying bimodally expressed genes from next-generation RNAseq data. We evaluate several candidate methods for modelling RNAseq count data and compare their performance in identifying bimodal genes through both simulation and real data analysis. We show that the lognormal mixture model performs best in terms of power and robustness under various scenarios. We also compare our method with alternative approaches, including profile analysis using clustering and kurtosis (PACK) and cancer outlier profile analysis (COPA). Our method is robust, powerful, invariant to shifting and scaling, has no blind spots and has a sample-size-free interpretation. AVAILABILITY: The R package SIBER is available at the website http://bioinformatics.mdanderson.org/main/OOMPA:Overview.
Pan Tong, Yong Chen 0016, Kevin R. Coombes
Bioinform.1
2012 integIRTy: a method to identify genes altered in cancer by accounting for multiple mechanisms of regulation using item response theory
abstract
MOTIVATION: Identifying genes altered in cancer plays a crucial role in both understanding the mechanism of carcinogenesis and developing novel therapeutics. It is known that there are various mechanisms of regulation that can lead to gene dysfunction, including copy number change, methylation, abnormal expression, mutation and so on. Nowadays, all these types of alterations can be simultaneously interrogated by different types of assays. Although many methods have been proposed to identify altered genes from a single assay, there is no method that can deal with multiple assays accounting for different alteration types systematically. RESULTS: In this article, we propose a novel method, integration using item response theory (integIRTy), to identify altered genes by using item response theory that allows integrated analysis of multiple high-throughput assays. When applied to a single assay, the proposed method is more robust and reliable than conventional methods such as Student's t-test or the Wilcoxon rank-sum test. When used to integrate multiple assays, integIRTy can identify novel-altered genes that cannot be found by looking at individual assay separately. We applied integIRTy to three public cancer datasets (ovarian carcinoma, breast cancer, glioblastoma) for cross-assay type integration which all show encouraging results. AVAILABILITY AND IMPLEMENTATION: The R package integIRTy is available at the web site http://bioinformatics.mdanderson.org/main/OOMPA:Overview. CONTACT: [email protected]. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Pan Tong, Kevin R. Coombes
Bioinform.1